KATP channel expression and pharmacological in vivo and in vitro studies of the KATP channel blocker PNU-37883A in rat middle meningeal arteries

British Journal of Pharmacology

Volumn 154, Issue 1, 2008, Pages 72-81

  Ploug, K B ^a,c   Boni, L J ^a   Baun, M ^a   Hay Schmidt, A ^b   Olesen, J ^a   Jansen Olesen, I ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Middle meningeal artery; Migraine; mRNA expression; PNU 37883A; Protein expression; Rat

Indexed keywords

2 CYANO 1 (1,1 DIMETHYLPROPYL) 3 (3 PYRIDYL)GUANIDINE; ADENOSINE TRIPHOSPHATASE (POTASSIUM); ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR6.1; LEMAKALIM; MESSENGER RNA; N (1 ADAMANTYL) N' CYCLOHEXYL 4 MORPHOLINECARBOXAMIDINE; PINACIDIL; SULFONYLUREA RECEPTOR; SULFONYLUREA RECEPTOR 2B;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG POTENCY; MALE; MENINGEAL ARTERY; MIGRAINE; MYOGRAPHY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ASSAY; RAT; REAL TIME POLYMERASE CHAIN REACTION; SPRAGUE DAWLEY RAT; WESTERN BLOTTING;

EID: 42949126382     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/bjp.2008.86     Document Type: Article

References (43)

1. Brian Jr JE, Faraci FM, Heistad DD (1996). Recent insights into the regulation of cerebral circulation. Clin Exp Pharmacol Physiol 23: 449–457.
2. D'Arcy V, Laher M, McCoy D, Sullivan P, Walsh CH, Hickey MP (1985). Pinacidil, a new vasodilator, in the treatment of mild to moderate essential hypertension. Eur J Clin Pharmacol 28: 347–349.
3. Doods H, Arndt K, Rudolf K, Just S (2007). CGRP antagonists: unravelling the role of CGRP in migraine. Trends Pharmacol Sci 28: 580–587.
4. Goldberg MR (1988). Clinical pharmacology of pinacidil, a prototype for drugs that affect potassium channels. J Cardiovasc Pharmacol 12 (Suppl 2): S41–S47.
5. Gozalov A, Petersen KA, Mortensen C, Jansen‐Olesen I, Klaerke D, Olesen J (2005). Role of KATP channels in the regulation of rat dura and pia artery diameter. Cephalalgia 25: 249–260.
6. Guillemare E, Honore E, De Weille J, Fosset M, Lazdunski M, Meisheri K (1994). Functional receptors in Xenopus oocytes for U‐37883A, a novel ATP‐sensitive K+ channel blocker: comparison with rat insulinoma cells. Mol Pharmacol 46: 139–145.
7. Hambrock A, Loffler‐Walz C, Kurachi Y, Quast U (1998). Mg 2+ and ATP dependence of K(ATP) channel modulator binding to the recombinant sulphonylurea receptor, SUR2B. Br J Pharmacol 125: 577–583.
8. Hempelmann RG, Barth HL, Mehdorn HM, Pradel RH, Ziegler A (1995). Effects of potassium channel openers in isolated human cerebral arteries. Neurosurgery 37: 1146–1153.
9. Humphrey SJ, Ludens JH, Perricone SC, Skaletzky LL, Graham BE, Zins GR (1995). Diuretic activity of N′‐disubstituted morpholinoguanidine analogs of U‐37883A in rats and dogs. Methods Find Exp Clin Pharmacol 17: 255–266.
10. Humphrey SJ, Smith MP, Cimini MG, Buchanan LV, Gibson JK, Khan SA et al. (1996). Cardiovascular effects of the K‐ATP channel blocker U‐37883A and structurally related morpholinoguanidines. Methods Find Exp Clin Pharmacol 18: 247–260.
11. Jansen‐Olesen I, Mortensen CH, El‐Bariaki N, Ploug KB (2005). Characterization of K(ATP)‐channels in rat basilar and middle cerebral arteries: studies of vasomotor responses and mRNA expression. Eur J Pharmacol 523: 109–118.
12. Kajioka S, Nakashima M, Kitamura K, Kuriyama H (1991). Mechanisms of vasodilatation induced by potassium‐channel activators. Clin Sci (Lond) 81: 129–139.
13. Kitazono T, Faraci FM, Taguchi H, Heistad DD (1995). Role of potassium channels in cerebral blood vessels. Stroke 26: 1713–1723.
14. Kleppisch T, Nelson MT (1995). ATP‐sensitive K + currents in cerebral arterial smooth muscle: pharmacological and hormonal modulation. Am J Physiol 269 (5 Part 2): H1634–H1640.
15. Kovalev H, Quayle JM, Kamishima T, Lodwick D (2004). Molecular analysis of the subtype‐selective inhibition of cloned KATP channels by PNU‐37883A. Br J Pharmacol 141: 867–873.
16. Ksoll E, Parsons AA, Mackert JR, Schilling L, Wahl M (1991). Analysis of cromakalim‐, pinacidil‐, and nicorandil‐induced relaxation of the 5‐hydroxytryptamine precontracted rat isolated basilar artery. Naunyn Schmiedebergs Arch Pharmacol 343: 377–383.
17. Lassen LH, Haderslev PA, Jacobsen VB, Iversen HK, Sperling B, Olesen J (2002). CGRP may play a causative role in migraine. Cephalalgia 22: 54–61.
18. Li L, Wu J, Jiang C (2003). Differential expression of Kir6.1 and SUR2B mRNAs in the vasculature of various tissues in rats. J Membr Biol 196: 61–69.
19. Ludens JH, Clark MA, Lawson JA (1995a). Effects of a K+ channel blocker on glomerular filtration rate and electrolyte excretion in conscious rats. J Pharmacol Exp Ther 273: 1375–1381.
20. Ludens JH, Clark MA, Smith MP, Humphrey SJ (1995b). Renal and vascular effects of chemically distinct ATP‐sensitive K + channel blockers in rats. J Cardiovasc Pharmacol 25: 404–409.
21. Meisheri KD, Humphrey SJ, Khan SA, Cipkus‐Dubray LA, Smith MP, Jones AW (1993). 4‐morpholinecarboximidine‐ N ‐1‐adamantyl‐ N ′‐cyclohexylhydrochloride (U‐37883A): pharmacological characterization of a novel antagonist of vascular ATP‐sensitive K + channel openers. J Pharmacol Exp Ther 266: 655–665.
22. Moskowitz MA (1991). The visceral organ brain: implications for the pathophysiology of vascular head pain. Neurology 41 (2 Part 1): 182–186.
23. Muiesan G, Fariello R, Muiesan ML, Christensen OE (1985). Effect of pinacidil on blood pressure, plasma catecholamines and plasma renin activity in essential hypertension. Eur J Clin Pharmacol 28: 495–499.
24. Nagao T, Ibayashi S, Sadoshima S, Fujii K, Fujii K, Ohya Y et al. (1996). Distribution and physiological roles of ATP‐sensitive K+ channels in the vertebrobasilar system of the rabbit. Circ Res 78: 238–243.
25. Nichols CG, Lederer WJ (1991). Adenosine triphosphate‐sensitive potassium channels in the cardiovascular system. Am J Physiol 261 (6 Part 2): H1675–H1686.
26. Ohrnberger CE, Khan SA, Meisheri KD (1993). Synergistic effects of glyburide and U‐37883A, two structurally different vascular ATP‐sensitive potassium channel antagonists. J Pharmacol Exp Ther 267: 25–30.
27. Parsons AA, Ksoll E, Mackert JR, Schilling L, Wahl M (1991). Comparison of cromakalim‐induced relaxation of potassium precontracted rabbit, cat, and rat isolated cerebral arteries. Naunyn Schmiedebergs Arch Pharmacol 343: 384–392.
28. Perricone SC, Humphrey SJ, Skaletzky LL, Graham BE, Zandt RA, Zins GR (1994). Synthesis and diuretic activity of alkyl‐ and arylguanidine analogs of N, N ′‐dicyclohexyl‐4‐morpholinecarboxamidine in rats and dogs. J Med Chem 37: 3693–3700.
29. Petersen KA, Dyrby L, Williamson D, Edvinsson L, Olesen J (2005). Effect of hypotension and carbon dioxide changes in an improved genuine closed cranial window rat model. Cephalalgia 25: 23–29.
30. Ploug KB, Edvinsson L, Olesen J, Jansen‐Olesen I (2006). Pharmacological and molecular comparison of K(ATP) channels in rat basilar and middle cerebral arteries. Eur J Pharmacol 553: 254–262.
31. Ray BS, Wolff HG (1940). Experimental studies on headache: pain sensitive structures of the head and their significance in headache. Arch Surg 41: 813–856.
32. Schwanstecher M, Sieverding C, Dorschner H, Gross I, Aguilar‐Bryan L, Schwanstecher C et al. (1998). Potassium channel openers require ATP to bind to and act through sulfonylurea receptors. EMBO J 17: 5529–5535.
33. Singer DR, Markandu ND, Miller MA, Sugden AL, MacGregor GA (1989). Potassium channel stimulation in normal subjects and in patients with essential hypertension: an acute study with cromakalim (BRL 34915). J Hypertens Suppl 7: S294–S295.
34. Smith MP, Humphrey SJ, Jackson WF (1994). Selective in vivo antagonism of pinacidil‐induced hypotension by the guanidine U37883A in anesthetized rats. Pharmacology 49: 363–375.
35. Sterndorff B, Johansen P (1988). The antihypertensive effect of pinacidil versus prazosin in mild to moderate hypertensive patients seen in general practice. Acta Med Scand 224: 329–336.
36. Stockbridge N, Zhang H, Weir B (1991). Effects of K + channel agonists cromakalim and pinacidil on rat basilar artery smooth muscle cells are mediated by Ca(++)‐activated K + channels. Biochem Biophys Res Commun 181: 172–178.
37. Surah‐Narwal S, Xu SZ, McHugh D, McDonald RL, Hough E, Cheong A et al. (1999). Block of human aorta Kir6.1 by the vascular KATP channel inhibitor U37883A. Br J Pharmacol 128: 667–672.
38. Suzuki S, Yano K, Kusano S, Hashimoto T (1995). Antihypertensive effect of levcromakalim in patients with essential hypertension. Study by 24‐h ambulatory blood pressure monitoring. Arzneimittelforschung 45: 859–864.
39. Teramoto N (2006). Pharmacological profile of U‐37883A, a channel blocker of smooth muscle‐type ATP‐sensitive K channels. Cardiovasc Drug Rev 24: 25–32.
40. Van Breemen C, Saida K (1989). Cellular mechanisms regulating [Ca2+]i smooth muscle. Annu Rev Physiol 51: 315–329.
41. Wellman GC, Quayle JM, Standen NB (1998). ATP‐sensitive K + channel activation by calcitonin gene‐related peptide and protein kinase A in pig coronary arterial smooth muscle. J Physiol 507 (Part 1): 117–129.
42. Williams AJ, Lee TH, Cochrane GM, Hopkirk A, Vyse T, Chiew F et al. (1990). Attenuation of nocturnal asthma by cromakalim. Lancet 336: 334–336.
43. Zachariah PK, Sheps SG, Schirger A, Fisher LD, Shub C, Collins JB et al. (1986). Antihypertensive efficacy of pinacidil—automatic ambulatory blood pressure monitoring. Eur J Clin Pharmacol 31: 133–141.